Exchange: NASDAQ·Updated 11:28 AM EST
OCS logo

OCS Oculis Holding AG

$7.41
$0.09
(1.20%)
Today
Reported EarningsNov 3
Mkt Cap$462.99M
Vol88,784.00

About OCS

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
42

Bearish Sentiment

How do you feel about OCS?

Compassbuyer
$OCS 5$ by the end of the year... that's the price I'll get some... hopefully it recovers in Q2 2027.
1
Merlintrader
Latest company news, October 19, 2026: Oculis completed randomization in PREDICT-1 of licaminlimab in dry eye disease (176 patients). Topline still expected around year-end 2026. An operational milestone, not data. Oculis Holding AG $OCS: Pipeline, Cash And Clinical Tests Deeper dive in our hub. Not investment advice.

Advertisement|Remove ads.